Poseida Therapeutics, Inc.
NASDAQ:PSTX
3.07 (USD) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 64.703 | 130.362 | 0.031 | 0 | 0 | 0 | 2.985 | 9.768 |
| Cost of Revenue
| 5.614 | 5.172 | 4.552 | 2.586 | 1.193 | 0.689 | 0 | 0 |
| Gross Profit
| 59.089 | 125.19 | -4.521 | -2.586 | -1.193 | -0.689 | 2.985 | 9.768 |
| Gross Profit Ratio
| 0.913 | 0.96 | -144.72 | 0 | 0 | 0 | 1 | 1 |
| Reseach & Development Expenses
| 156.772 | 152.899 | 0.137 | 0.104 | 60.393 | 30.883 | 19.099 | 9.864 |
| General & Administrative Expenses
| 37.435 | 37.539 | 0.036 | 0.023 | 18.457 | 9.674 | 5.479 | 5.353 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.22 |
| SG&A
| 37.435 | 37.539 | 0.036 | 0.023 | 18.457 | 9.674 | 5.479 | 5.133 |
| Other Expenses
| 14.852 | 2.858 | 0.02 | 0 | 2.559 | -0.821 | 0.037 | 0 |
| Operating Expenses
| 194.207 | 190.438 | 0.173 | 0.127 | 78.85 | 40.557 | 24.578 | 14.997 |
| Operating Income
| -129.504 | -59.946 | -0.141 | -0.127 | -85.533 | -41.989 | -19.668 | -5.449 |
| Operating Income Ratio
| -2.002 | -0.46 | -4.527 | 0 | 0 | 0 | -6.589 | -0.558 |
| Total Other Income Expenses Net
| 6.181 | -3.512 | 0.016 | -0.003 | -0.994 | -2.253 | 1.962 | 0.109 |
| Income Before Tax
| -123.323 | -63.458 | -0.125 | -0.13 | -86.527 | -44.606 | -20.189 | -5.34 |
| Income Before Tax Ratio
| -1.906 | -0.487 | -4.001 | 0 | 0 | 0 | -6.763 | -0.547 |
| Income Tax Expense
| -0.107 | 0.544 | -4.529 | -2.582 | 6.112 | -0.202 | -0.527 | -0.765 |
| Net Income
| -123.43 | -64.002 | 4.404 | 2.452 | -92.639 | -44.404 | -19.662 | -4.575 |
| Net Income Ratio
| -1.908 | -0.491 | 140.978 | 0 | 0 | 0 | -6.587 | -0.468 |
| EPS
| -1.37 | -0.89 | 0.071 | 0.068 | -2.33 | -1.24 | -0.49 | -0.077 |
| EPS Diluted
| -1.37 | -0.89 | 0.071 | 0.068 | -2.33 | -1.24 | -0.49 | -0.077 |
| EBITDA
| -129.504 | -57.088 | -0.122 | -0.126 | -75.098 | -40.689 | -20.88 | -5.229 |
| EBITDA Ratio
| -2.002 | -0.438 | -3.893 | 0 | 0 | 0 | -6.995 | -0.535 |